No matches
Dermatology

Immunological Drivers in CSU: Diverse Pathways to Mast Cell Activation

In this video from EADV 2025, Dr. Hawkes reviews the pathophysioogy of CSU with a focus on the role of type 2 inflammation
Jason Hawkes
MD, MS
Jason Hawkes

Related resources

Emerging Therapeutic Landscape and Implications for Patient Management in CSU

Emerging Therapeutic Landscape and Implications for Patient Management in CSU

expert video
Mast Cells and the Neuroimmune Axis in CSU

Mast Cells and the Neuroimmune Axis in CSU

expert video
UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis

UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis

expert video
Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

videoanimation
What is Early Intervention in AD?

What is Early Intervention in AD?

expert video
Disease Modification in AD

Disease Modification in AD

expert video
Systemic Inflammation in AD – Beyond the Skin

Systemic Inflammation in AD – Beyond the Skin

expert video
Dysbiosis, Skin Infections, and Itch

Dysbiosis, Skin Infections, and Itch

expert video
Skin Barrier Dysfunction in AD

Skin Barrier Dysfunction in AD

expert video
Early Intervention and the Potential for Disease Modification in Children With AD

Early Intervention and the Potential for Disease Modification in Children With AD

expert video
Emerging Data on Advanced Systemic Treatments for Children With AD

Emerging Data on Advanced Systemic Treatments for Children With AD

expert video
Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

expert video
Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?

Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?

expert video
New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management

New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management

expert video
New Perspectives in Understanding Pathophysiology of Atopic Dermatitis in Children

New Perspectives in Understanding Pathophysiology of Atopic Dermatitis in Children

expert video
Current Treatment Landscape and Emerging Therapies

Current Treatment Landscape and Emerging Therapies

expert video
Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization May Impact Atopic March in Atopic Dermatitis (AD)

Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization May Impact Atopic March in Atopic Dermatitis (AD)

Infographic
The Potential Long-term Consequences in AD in Children: Cardiovascular Risk, Bone Health, and Mental Health

The Potential Long-term Consequences in AD in Children: Cardiovascular Risk, Bone Health, and Mental Health

expert video
The Relationship Between Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization in AD

The Relationship Between Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization in AD

expert video
How Can We Explore the Concept of Disease Modification in Children With AD?

How Can We Explore the Concept of Disease Modification in Children With AD?

expert video
Overview of Type 2 Inflammation in the Presentations of AD, PN, and CSU

Overview of Type 2 Inflammation in the Presentations of AD, PN, and CSU

expert video
Differences in Itch in AD, PN, and CSU

Differences in Itch in AD, PN, and CSU

expert video
Contribution of Type 2 Cytokines to Inflammation and Itch in AD, PN, and CSU 

Contribution of Type 2 Cytokines to Inflammation and Itch in AD, PN, and CSU 

expert video
Itch in AD, PN and CSU: Role of Type 2 Inflammation

Itch in AD, PN and CSU: Role of Type 2 Inflammation

expert video
Clinical Presentations in AD, PN, and CSU: Role of Type 2 Inflammation

Clinical Presentations in AD, PN, and CSU: Role of Type 2 Inflammation

expert video
Shared and Unique Characteristics of AD, PN, and CSU

Shared and Unique Characteristics of AD, PN, and CSU

expert video
Emerging Understanding of Chronic Itchy Skin Diseases – Shared and Unique Drivers in AD, PN, and CSU

Emerging Understanding of Chronic Itchy Skin Diseases – Shared and Unique Drivers in AD, PN, and CSU

Infographic
Emerging Understanding of Chronic Itchy Skin Diseases: Shared and Unique Drivers in AD, PN, and CSU

Emerging Understanding of Chronic Itchy Skin Diseases: Shared and Unique Drivers in AD, PN, and CSU

expert video
New Perspectives on Disease Modification in Atopic Dermatitis - Panel Discussion

New Perspectives on Disease Modification in Atopic Dermatitis - Panel Discussion

expert video
Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion

expert video
Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

expert video
Neuroimmune Axis in Atopic Dermatitis

Neuroimmune Axis in Atopic Dermatitis

expert video
New Perspectives on Disease Modification in Atopic Dermatitis

New Perspectives on Disease Modification in Atopic Dermatitis

expert video
Exploring The Concept of Disease Modification in Atopic Dermatitis

Exploring The Concept of Disease Modification in Atopic Dermatitis

expert video
The Impact of Advanced Systemic Therapies on Disease Control and Potential Remission in Atopic Dermatitis

The Impact of Advanced Systemic Therapies on Disease Control and Potential Remission in Atopic Dermatitis

expert video
Can Early Intervention Shape the Course of Atopic Dermatitis?

Can Early Intervention Shape the Course of Atopic Dermatitis?

expert video
UCARE 2023: Immune Cells and Mediators Essential for Driving CSU Pathology

UCARE 2023: Immune Cells and Mediators Essential for Driving CSU Pathology

expert video
UCARE 2023: Non-Histaminergic Neuronal Sensitization in CSU

UCARE 2023: Non-Histaminergic Neuronal Sensitization in CSU

expert video
UCARE 2023: Implications of Different Modes of Action of Dupilumab, Remibrutinib, and Barzolvolimab

UCARE 2023: Implications of Different Modes of Action of Dupilumab, Remibrutinib, and Barzolvolimab

expert video
UCARE 2023: Neuronal Involvement in CSU

UCARE 2023: Neuronal Involvement in CSU

expert video
UCARE 2023: Role of Type 2 Inflammation in CSU Pathogenesis 

UCARE 2023: Role of Type 2 Inflammation in CSU Pathogenesis 

expert video
UCARE 2023: Emerging Clinical Trial Data in CSU

UCARE 2023: Emerging Clinical Trial Data in CSU

expert video
UCARE 2023: CSU – The Brazil Perspective

UCARE 2023: CSU – The Brazil Perspective

expert video
UCARE 2023: Targeting Type 2 Inflammation in CSU – Clinical and Mechanistic Implications

UCARE 2023: Targeting Type 2 Inflammation in CSU – Clinical and Mechanistic Implications

expert video
UCARE 2023: Panel Discussion/Q&A

UCARE 2023: Panel Discussion/Q&A

expert video
Comorbidities and Clinical Management in CSU

Comorbidities and Clinical Management in CSU

expert video
Comorbidities and Disease Burden in CSU

Comorbidities and Disease Burden in CSU

expert video
Treatment Goals, Current and Emerging Therapies in CSU

Treatment Goals, Current and Emerging Therapies in CSU

expert video
Guideline and Patient Management in CSU

Guideline and Patient Management in CSU

expert video
The Current and Potential Future Roles of Biomarkers and Precision Medicine in CSU Clinical Management

The Current and Potential Future Roles of Biomarkers and Precision Medicine in CSU Clinical Management

expert video

Learning objectives

  • Describe the multifaceted pathophysiology of CSU, including key inflammatory mechanisms
Tags
type 2 inflammation
MAT-GLB-2506010 - 1.0 - 10/2025

About this expert

Dermatology

Jason Hawkes

MD, MS

Dr. Hawkes is a board-certified dermatologist and Investigator at the Oregon Medical Research Center in Portland, OR and is a current Councilor in the International Psoriasis Council and serves on the NPF Medical Board and Scientific Advisory Committee

See author’s profile
Jason Hawkes

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ChinaChange country/region